TNF and tuberculosis: As previously stated in this paper, based on the absence of evidence of an increased TB reactivation risk in patients with PsA receiving UTK or SCK, we suggest to use these non-anti-TNF-targeted biologics as first-line therapy in PsA patients with LTBI.